Literature DB >> 2471792

Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies.

J Arikawa1, A L Schmaljohn, J M Dalrymple, C S Schmaljohn.   

Abstract

A panel of 24 monoclonal antibodies (MAbs) to the G1 or G2 envelope glycoproteins of Hantaan virus were used to determine the surface topography and functional properties of antigenic sites. Nine distinct, partially overlapping antigenic sites, two on G1 and seven on G2, were demonstrated by competitive binding assays. Analyses of the antigenic sites by haemagglutination (HA) inhibition and plaque-reduction neutralization tests showed that all of the sites, except one on G1, were related to viral HA. Only one of the G1 antigenic sites and two of the G2 sites were involved in virus neutralization. These results suggest that certain epitopes related to HA were not critical for virus neutralization. The nine antigenic sites could be further divided into 13 based upon the serological cross-reactivity of MAbs with viruses representative of each of the four known antigenic groups within the Hantavirus genus of Bunyaviridae, i.e. Hantaan, Seoul, Puumala and Prospect Hill viruses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471792     DOI: 10.1099/0022-1317-70-3-615

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  49 in total

Review 1.  Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Authors:  Clayton A Wiley; Nitin Bhardwaj; Ted M Ross; Stephanie J Bissel
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

2.  Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein.

Authors:  P Gött; L Zöller; G Darai; E K Bautz
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

4.  Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants.

Authors:  C S Schmaljohn; Y K Chu; A L Schmaljohn; J M Dalrymple
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  Interactions and oligomerization of hantavirus glycoproteins.

Authors:  Jussi Hepojoki; Tomas Strandin; Antti Vaheri; Hilkka Lankinen
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

6.  Phage-displayed peptide targeting on the Puumala hantavirus neutralization site.

Authors:  T Heiskanen; A Lundkvist; A Vaheri; H Lankinen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro.

Authors:  Shuyang Yu; Mifang Liang; Baoliang Fan; Hongtao Xu; Chuan Li; Quanfu Zhang; Dexin Li; Bo Tang; Shijie Li; Yunping Dai; Meili Wang; Min Zheng; Bingxue Yan; Qinghong Zhu; Ning Li
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Phage display selection of cyclic peptides that inhibit Andes virus infection.

Authors:  Pamela R Hall; Brian Hjelle; Hadya Njus; Chunyan Ye; Virginie Bondu-Hawkins; David C Brown; Kathleen A Kilpatrick; Richard S Larson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

9.  Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking.

Authors:  Xiaohong Shi; Richard M Elliott
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Characterization of Imjin virus, a newly isolated hantavirus from the Ussuri white-toothed shrew (Crocidura lasiura).

Authors:  Jin-Won Song; Hae Ji Kang; Se Hun Gu; Sung Sil Moon; Shannon N Bennett; Ki-Joon Song; Luck Ju Baek; Heung-Chul Kim; Monica L O'Guinn; Sung-Tae Chong; Terry A Klein; Richard Yanagihara
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.